{
    "info": {
        "nct_id": "NCT03839524",
        "official_title": "A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.",
        "inclusion_criteria": "1. Signed written informed consent.\n2. Female patients ≥ 18 years\n3. Histologically confirmed high grade, advanced stage serous ovarian, fallopian tube or primary peritoneal carcinoma.\n4. Patients who have undergone primary debulking surgery or interval debulking surgery and have completed standard first-line platinum-based chemotherapy and for whom tumor tissue has been banked.\n5. Patients must have achieved a complete response to therapy\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at treatment period initiation\n7. Adequate hematological, hepatic and renal functions.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Patient having received any cancer immunotherapy including cancer vaccines, any antibody/drug targeting T cell co-regulatory proteins such as anti-Programmed cell death 1 (anti-PD1), anti-Programmed death-ligand 1 (anti-PDL1) or anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTL4)\n2. Patients with other active malignancy ≤ 3 years prior to registration except non-melanoma skin cancer, stage 0 in situ carcinoma.\n3. Patient post-organ transplantation, including allogeneic stem cell or bone marrow transplantation.\n4. Known history of positive testing for Human Immunodeficiency Virus (HIV) or known AIDS (Acquired Immune Deficiency Syndrome).\n5. Any known allergy or reaction to eggs or attributed to compounds of similar chemical or biological composition to therapeutic vaccines/immunotherapeutic products.\n6. Acute or chronic infection with hepatitis C Virus (HCV) or Hepatitis B Virus (HBV).\n7. Major surgery within 4 weeks of treatment start.\n8. Treatment with another investigation agent within 30 days prior to TG4050 treatment initiation.\n9. Patients under chronic treatment with systemic corticosteroids or other immunosuppressive drugs . Steroids with no or minimal systemic effect (topical, inhalation) are allowed.\n10. Use of live vaccine for the prevention of infectious diseases during the four-week period prior to TG4050 treatment initiation planned date. Furthermore, patients should not receive any live vaccine during the period of study treatment administration.\n11. Uncontrolled intercurrent illness.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "3. Histologically confirmed high grade, advanced stage serous ovarian, fallopian tube or primary peritoneal carcinoma.",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "histology"
                        }
                    ]
                },
                {
                    "exact_snippets": "high grade",
                    "criterion": "tumor grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "high"
                        }
                    ]
                },
                {
                    "exact_snippets": "advanced stage",
                    "criterion": "tumor stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        }
                    ]
                },
                {
                    "exact_snippets": "serous ovarian, fallopian tube or primary peritoneal carcinoma",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "serous ovarian carcinoma",
                                "serous fallopian tube carcinoma",
                                "serous primary peritoneal carcinoma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Female patients ≥ 18 years",
            "criterions": [
                {
                    "exact_snippets": "Female patients",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at treatment period initiation",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at treatment period initiation",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Patients must have achieved a complete response to therapy",
            "criterions": [
                {
                    "exact_snippets": "achieved a complete response to therapy",
                    "criterion": "response to therapy",
                    "requirements": [
                        {
                            "requirement_type": "response type",
                            "expected_value": "complete response"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Signed written informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Signed written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "written",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Patients who have undergone primary debulking surgery or interval debulking surgery and have completed standard first-line platinum-based chemotherapy and for whom tumor tissue has been banked.",
            "criterions": [
                {
                    "exact_snippets": "Patients who have undergone primary debulking surgery or interval debulking surgery",
                    "criterion": "debulking surgery",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": [
                                "primary debulking surgery",
                                "interval debulking surgery"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have completed standard first-line platinum-based chemotherapy",
                    "criterion": "platinum-based chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "completion of standard first-line treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for whom tumor tissue has been banked",
                    "criterion": "tumor tissue banking",
                    "requirements": [
                        {
                            "requirement_type": "banked",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Adequate hematological, hepatic and renal functions.",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematological ... functions",
                    "criterion": "hematological function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... hepatic ... functions",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal functions",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "11. Uncontrolled intercurrent illness.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled intercurrent illness",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Patient post-organ transplantation, including allogeneic stem cell or bone marrow transplantation.",
            "criterions": [
                {
                    "exact_snippets": "Patient post-organ transplantation",
                    "criterion": "organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history of",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including allogeneic stem cell or bone marrow transplantation",
                    "criterion": "allogeneic stem cell or bone marrow transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history of",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Major surgery within 4 weeks of treatment start.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks of treatment start.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Any known allergy or reaction to eggs or attributed to compounds of similar chemical or biological composition to therapeutic vaccines/immunotherapeutic products.",
            "criterions": [
                {
                    "exact_snippets": "Any known allergy or reaction to eggs",
                    "criterion": "allergy or reaction to eggs",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allergy or reaction ... attributed to compounds of similar chemical or biological composition to therapeutic vaccines/immunotherapeutic products",
                    "criterion": "allergy or reaction to compounds of similar chemical or biological composition to therapeutic vaccines/immunotherapeutic products",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Acute or chronic infection with hepatitis C Virus (HCV) or Hepatitis B Virus (HBV).",
            "criterions": [
                {
                    "exact_snippets": "Acute or chronic infection with hepatitis C Virus (HCV)",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "acute",
                                "chronic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Acute or chronic infection with ... Hepatitis B Virus (HBV)",
                    "criterion": "hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "acute",
                                "chronic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Treatment with another investigation agent within 30 days prior to TG4050 treatment initiation.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with another investigation agent within 30 days prior to TG4050 treatment initiation.",
                    "criterion": "treatment with another investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to TG4050 treatment initiation"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Known history of positive testing for Human Immunodeficiency Virus (HIV) or known AIDS (Acquired Immune Deficiency Syndrome).",
            "criterions": [
                {
                    "exact_snippets": "Known history of positive testing for Human Immunodeficiency Virus (HIV)",
                    "criterion": "Human Immunodeficiency Virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history of positive testing",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known AIDS (Acquired Immune Deficiency Syndrome)",
                    "criterion": "AIDS (Acquired Immune Deficiency Syndrome)",
                    "requirements": [
                        {
                            "requirement_type": "history of diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Patient having received any cancer immunotherapy including cancer vaccines, any antibody/drug targeting T cell co-regulatory proteins such as anti-Programmed cell death 1 (anti-PD1), anti-Programmed death-ligand 1 (anti-PDL1) or anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTL4)",
            "criterions": [
                {
                    "exact_snippets": "Patient having received any cancer immunotherapy including cancer vaccines",
                    "criterion": "prior cancer immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any antibody/drug targeting T cell co-regulatory proteins such as anti-Programmed cell death 1 (anti-PD1), anti-Programmed death-ligand 1 (anti-PDL1) or anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTL4)",
                    "criterion": "prior treatment with antibody/drug targeting T cell co-regulatory proteins",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "targeted proteins",
                            "expected_value": [
                                "PD1",
                                "PDL1",
                                "CTL4"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Patients under chronic treatment with systemic corticosteroids or other immunosuppressive drugs . Steroids with no or minimal systemic effect (topical, inhalation) are allowed.",
            "criterions": [
                {
                    "exact_snippets": "Patients under chronic treatment with systemic corticosteroids or other immunosuppressive drugs",
                    "criterion": "chronic treatment with systemic corticosteroids or other immunosuppressive drugs",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Steroids with no or minimal systemic effect (topical, inhalation) are allowed",
                    "criterion": "steroids with no or minimal systemic effect (topical, inhalation)",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Use of live vaccine for the prevention of infectious diseases during the four-week period prior to TG4050 treatment initiation planned date. Furthermore, patients should not receive any live vaccine during the period of study treatment administration.",
            "criterions": [
                {
                    "exact_snippets": "Use of live vaccine for the prevention of infectious diseases during the four-week period prior to TG4050 treatment initiation planned date",
                    "criterion": "use of live vaccine",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks before TG4050 treatment initiation"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients should not receive any live vaccine during the period of study treatment administration",
                    "criterion": "use of live vaccine",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": "during the period of study treatment administration"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients with other active malignancy ≤ 3 years prior to registration except non-melanoma skin cancer, stage 0 in situ carcinoma.",
            "criterions": [
                {
                    "exact_snippets": "Patients with other active malignancy ≤ 3 years prior to registration except non-melanoma skin cancer, stage 0 in situ carcinoma.",
                    "criterion": "other active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "non-melanoma skin cancer",
                                "stage 0 in situ carcinoma"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}